<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74623</article-id><article-id pub-id-type="doi">10.7554/eLife.74623</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>ACE2 is the critical <italic>in vivo</italic> receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-256595"><name><surname>Gawish</surname><given-names>Riem</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4267-2131</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258058"><name><surname>Starkl</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258059"><name><surname>Pimenov</surname><given-names>Lisabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258060"><name><surname>Hladik</surname><given-names>Anastasiya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258061"><name><surname>Lakovits</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258062"><name><surname>Oberndorfer</surname><given-names>Felicitas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258064"><name><surname>Cronin</surname><given-names>Shane JF</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52213"><name><surname>Ohradanova-Repic</surname><given-names>Anna</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8005-8522</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254463"><name><surname>Wirnsberger</surname><given-names>Gerald</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258065"><name><surname>Agerer</surname><given-names>Benedikt</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258066"><name><surname>Endler</surname><given-names>Lukas</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258067"><name><surname>Capraz</surname><given-names>Tümay</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254457"><name><surname>Perthold</surname><given-names>Jan W</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33774"><name><surname>Cikes</surname><given-names>Domagoj</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265622"><name><surname>Koglgruber</surname><given-names>Rubina</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258068"><name><surname>Hagelkruys</surname><given-names>Astrid</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247849"><name><surname>Montserrat</surname><given-names>Nuria</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-152982"><name><surname>Mirazimi</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219210"><name><surname>Boon</surname><given-names>Louis</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258070"><name><surname>Stockinger</surname><given-names>Hannes</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6404-4430</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258071"><name><surname>Bergthaler</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183997"><name><surname>Oostenbrink</surname><given-names>Chris</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4232-2556</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-212735"><name><surname>Penninger</surname><given-names>Josef M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-258072"><name><surname>Knapp</surname><given-names>Sylvia</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9016-5244</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Medicine I</institution>, <institution>Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff2"><institution content-type="dept">Department of Pathology</institution>, <institution>Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff3"><institution content-type="dept">Institute of Molecular Biotechnology</institution>, <institution>Austrian Academy of Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff4"><institution content-type="dept">Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology</institution>, <institution>Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff5"><institution>Apeiron Biologics AG</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff6"><institution content-type="dept">CeMM, Research Center for Molecular Medicine</institution>, <institution>Austrian Academy of Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff7"><institution content-type="dept">Institute for Molecular Modeling and Simulation</institution>, <institution>University of Natural Resources and Life Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff8"><institution content-type="dept">Pluripotency for Organ Regeneration</institution>, <institution>Institute for Bioengineering of Catalonia</institution>, <addr-line><named-content content-type="city">Barcelona</named-content></addr-line>, <country>Spain</country></aff><aff id="aff9"><institution content-type="dept">Department of Laboratory Medicine</institution>, <institution>Karolinska Institute</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff10"><institution>Polpharma Biologics</institution>, <addr-line><named-content content-type="city">Utrecht</named-content></addr-line>, <country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-21373"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing editor</role><aff><institution>Ulm University Medical Center</institution>, <country>Germany</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Sylvia.knapp@meduniwien.ac.at</email> (SK);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>01</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e74623</elocation-id><history><date date-type="received"><day>11</day><month>10</month><year>2021</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Gawish et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Gawish et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74623-v1.pdf"/><abstract><p>In silico modelling revealed how only three Spike mutations of maVie16 enhanced interaction with murine ACE2. MaVie16 induced profound pathology in BALB/c and C57BL/6 mice and the resulting mouse COVID-19 (mCOVID-19) replicated critical aspects of human disease, including early lymphopenia, pulmonary immune cell infiltration, pneumonia and specific adaptive immunity. Inhibition of the proinflammatory cytokines IFNg and TNF substantially reduced immunopathology. Importantly, genetic ACE2-deficiency completely prevented mCOVID-19 development. Finally, inhalation therapy with recombinant ACE2 fully protected mice from mCOVID-19, revealing a novel and efficient treatment. Thus, we here present maVie16 as a new tool to model COVID-19 for the discovery of new therapies and show that disease severity is determined by cytokine-driven immunopathology and critically dependent on ACE2 <italic>in vivo</italic>.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>F54-10 and F61-04</award-id><principal-award-recipient><name><surname>Knapp</surname><given-names>Sylvia</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010767</institution-id><institution>Innovative Medicines Initiative</institution></institution-wrap></funding-source><award-id>101005026</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>ZK57-B28</award-id><principal-award-recipient><name><surname>Gawish</surname><given-names>Riem</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P31113-B30</award-id><principal-award-recipient><name><surname>Starkl</surname><given-names>Philipp</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P 34253-B</award-id><principal-award-recipient><name><surname>Ohradanova-Repic</surname><given-names>Anna</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P 34253-B</award-id><principal-award-recipient><name><surname>Stockinger</surname><given-names>Hannes</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>DK W1212</award-id><principal-award-recipient><name><surname>Agerer</surname><given-names>Benedikt</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>Z 271-B19</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001804</institution-id><institution>Canada Research Chairs</institution></institution-wrap></funding-source><award-id>F18-01336</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>F20-02343 and F20-02015</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Gerald Wirnsberger, is an employee of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients..</p></fn><fn fn-type="conflict" id="conf3"><p>Josef M Penninger, declares a conflict of interest as a founder and shareholder of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients.(patent #WO2021191436A1)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experiments involving SARS-CoV-2 or its derivatives were performed in Biosafety Level 3 (BSL-3) facilities at the Medical University of Vienna and performed according to the ethical guidelines and after approval by the institutional review board of the Austrian Ministry of Sciences (BMBWF-2020-0.253.770) and in accordance with the directives of the EU.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>maVie16 SARS-CoV-2 genome sequence will be published on: https://www.ebi.ac.uk/enaProjectaccession: PRJEB46926</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>CEMM RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES</collab></person-group><year iso-8601-date="2021">2021</year><source>Exploring COVID-19 disease, immunity and therapeutic options in mice using maVie16, a host-adapted SARS-CoV-2</source><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB46926">https://www.ebi.ac.uk/ena/browser/view/PRJEB46926</ext-link><comment>European Nucleotide Archive (ENA), PRJEB46926</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-74623-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>